ProCE Banner Series

PARP Inhibitors in Advanced Prostate Cancer: Overcoming Global Challenges in Testing and Treatment

Join us for this conversational, CME-certified webinar featuring international experts discussing key areas of consensus and controversy around the latest data, testing, new indications, and emerging novel PARP inhibitor combination regimens for prostate cancer. Bring your questions!

  AMA
Who Should Attend

This program is intended for oncologists and other healthcare professionals who provide care for patients with prostate cancer.

All Events

PARP Inhibitors in Advanced Prostate Cancer: Overcoming Global Challenges in Testing and Treatment

Upcoming Events

May

15

2024

5:30 PM - 6:30 PM Central European Summer Time (CEST)

Virtual

Faculty

ProCE Banner Faculty
Karim Fizazi, MD, PhD

Full Professor
Cancer Medicine
Gustave Roussey
Villejuif, France

ProCE Banner Faculty
Joaquin Mateo, MD, PhD

Medical Oncology Department
Vall d’Hebron University Hospital
Group Leader
Vall d’Hebron Institute of Oncology
Barcelona, Spain

Topics

  • Molecular Biomarker Testing in Patients With Prostate Cancer: Challenges and Recommendations
  • Aligning Prostate Cancer Clinical Practice With Recent Findings and Expert Recommendations Regarding PARP Inhibitor–Based Combination Regimens
  • Managing Adverse Events Associated With PARP Inhibitor–Based Combination Regimens for Prostate Cancer in Practice
  • Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the competence of HCPs at employing PARP inhibitor-based combination regimens in the treatment of patients with prostate cancer.

Target Audience
This program is intended for oncologists and other healthcare professionals who provide care for patients with prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Integrate current molecular biomarker tests into clinical practice to identify patients with prostate cancer who are candidates for PARP inhibitor therapy
  • Apply PARP inhibitor–based combination regimens in the treatment of patients with prostate cancer taking into account recent guideline updates, recent data, and expert recommendations
  • Appropriately manage adverse events associated with PARP inhibitor combination regimens to improve quality of life, adherence, and outcomes in patients with prostate cancer
  • Refer appropriate patients to clinical trials of PARP inhibitor-based combination regimens for the treatment of prostate cancer

Accreditation

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

Supported by an educational grant from Pfizer Inc.